Pharmacokinetic Interactions between Canagliflozin and Sorafenib or Lenvatinib in Rats

Hepatocellular carcinoma (HCC) and type 2 diabetes mellitus (T2DM) are common clinical conditions, and T2DM is an independent risk factor for HCC. Sorafenib and lenvatinib, two multi-targeted tyrosine kinase inhibitors, are first-line therapies for advanced HCC, while canagliflozin, a sodium-glucose...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Yanjun, Li, Ying, Guo, Caihui, Li, Yajing, Ma, Yinling, Dong, Zhanjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9457773/
https://www.ncbi.nlm.nih.gov/pubmed/36080187
http://dx.doi.org/10.3390/molecules27175419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9457773/
https://www.ncbi.nlm.nih.gov/pubmed/36080187
http://dx.doi.org/10.3390/molecules27175419

Ejemplares similares